Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles
NCT ID: NCT04124913
Last Updated: 2019-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
140 participants
INTERVENTIONAL
2019-01-02
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Luteal Support in Frozen-Thawed Embryo Transfer Cycles
NCT03948022
Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles
NCT02492451
Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer
NCT03832699
The Effects of Estrogen on Artificial Endometrium
NCT03155048
Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
NCT04758871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dydrogesterone
Dydrogesterone 10 MG Oral Tablet
Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Vaginal progesterone
Progesterone Vaginal Gel [Crinone]
Vaginal progesterone gel 90 mg once a day for luteal phase support
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dydrogesterone 10 MG Oral Tablet
Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Progesterone Vaginal Gel [Crinone]
Vaginal progesterone gel 90 mg once a day for luteal phase support
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Modified natural frozen- thawed embryo transfer cycles
Exclusion Criteria
* Recurrent pregnancy loss
* Presence of uterine pathology
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sisli Hospital, Istanbul
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gönül Özer
Medical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Semra Kahraman, Prof
Role: PRINCIPAL_INVESTIGATOR
Memorial Şişli Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Şişli Hospital
Istanbul, Şişli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.